Novo Nordisk (CPSE:NOVO B) uses OpenAI's Rosalind AI model in its drug discovery work, tying its R&D to OpenAI's tech stack. OpenAI has acquired Orchestra Bio to strengthen Rosalind's life sciences capabilities used by pharmaceutical groups including Novo Nordisk. The deal focuses on applying AI to areas such as target identification, molecule design and trial analytics for Novo Nordisk's pipeline work. OpenAI's purchase of Orchestra Bio to reinforce Rosalind for Novo Nordisk's research is worth weighing against the rest of our findings. We have also flagged 2 warning signs (1 major) for Novo Nordisk. For more context on how AI infrastructure could shape outcomes for Novo Nordisk's peers, explore 55 AI infrastructure stocks.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.